Main functions and effects of Quizartinib

Quizartinib is a selective, oral, small-molecule tyrosine kinase inhibitor specifically targeting patients with acute myeloid leukemia (AML) who are positive for FLT3 internal tandem duplication (ITD) mutations. FLT3 is a receptor tyrosine kinase expressed in hematopoietic stem cells and myeloid cells. Its mutations can lead to abnormal proliferation of leukemia cells and overactivation of survival signals, thereby accelerating the development of AML. Quizartinib can effectively block this signaling pathway by highly selectively inhibiting the kinase activity of FLT3-ITD, thereby inhibiting the proliferation and survival of leukemia cells.

In clinical application, quizartinib can not only be combined with standard cytarabine and anthracyclines for induction chemotherapy, but can also be used as maintenance monotherapy after consolidation chemotherapy to help extend the remission period and reduce the risk of recurrence. The strategy of combination chemotherapy aims to eliminate most leukemia cells through short-term high-intensity treatment, and as maintenance therapy, quizartinib can continue to exert an inhibitory effect on the remaining FLT3-ITD mutated leukemia cells, thereby reducing the recurrence rate and improving the long-term survival rate of patients.

The oral administration method improves the convenience of patients during treatment. At the same time, the dosage can be flexibly adjusted according to the course of treatment to adapt to the tolerance and hematological conditions of different patients. Research and overseas practice have shown that quizartinib shows high specificity and good efficacy in patients with FLT3-ITD-positive AML, providing a new treatment option for refractory or high-risk AML. In the treatment plan, quizartinib not only acts on leukemia cells in the bone marrow and peripheral blood, but also inhibits leukemia support signals in the microenvironment to a certain extent, thereby further improving the therapeutic effect.

In summary, quizartinib provides a systemic treatment strategy for newly diagnosed high-risk AML patients by precisely inhibiting theFLT3-ITD signaling pathway, combined with standard chemotherapy and maintenance monotherapy. In the future, with the accumulation of more clinical practice and research, the status and application scope of quizartinib in the treatment of AML is expected to be further expanded.

References：https://www.medicines.org.uk/emc/product/15557/smpc